On March 19, 2025, Century Therapeutics, Inc. (NASDAQ: IPSC), a biotechnology firm specializing in induced pluripotent stem cell (iPSC)-derived therapies for autoimmune diseases and cancer, announced its financial results for the full year 2024 along with a strategic business update. The company's leadership emphasized a new direction aimed at prioritizing high-impact therapies that address significant unmet medical needs.

1. Strategic Re-Prioritization of Clinical Pipeline

Brent Pfeiffenberger, Pharm.D., CEO of Century Therapeutics, articulated the company's commitment to refining its pipeline by focusing on candidates that hold promise for being transformational or best-in-class. This strategic shift will leverage Century's strong cash position to facilitate progress toward critical milestones.

The CEO stated, "We have made the strategic decision to discontinue the Phase 1 ELiPSE-1 trial early... We believe CNTY-101 is well-positioned to potentially impact the standard of care meaningfully in B-cell-mediated autoimmune diseases." This decision reflects the company's commitment to resource allocation toward programs that demonstrate significant potential.

Key Initiatives and Clinical Trials

CALiPSO-1 Trial Expansion: Century announced the enrollment of the first patient in the CALiPSO-1 Phase 1 trial targeting autoimmune diseases, with dosing scheduled for March 2025. The trial will expand to additional sites in the U.S. and select European countries, with increased efforts to enhance patient enrollment.

CARAMEL Investigator-Initiated Trial (IIT): In a significant advancement, Century disclosed an agreement for a Phase 1/2 trial led by renowned researchers Professors Georg Schett and Andreas Mackensen, which will evaluate CNTY-101 in patients with B-cell mediated autoimmune diseases. This IIT is expected to begin in mid-2025 following Clinical Trial Authorization (CTA) approval.

Discontinuation of ELiPSE-1 Program: Although the clinical data from the ELiPSE-1 trial showed promising activity and tolerability for CNTY-101 in relapsed/refractory non-Hodgkin’s lymphoma (R/R NHL), the company determined that the results did not meet its threshold for transformation in this patient population. Nonetheless, the company will continue to provide treatment access to patients benefiting from the trial.

2. Financial Overview for Full Year 2024

Century Therapeutics reported a cash position of $220.1 million as of December 31, 2024, a decrease from $261.8 million the previous year. The company projects that its cash reserves will support operations through the fourth quarter of 2026.

Key Financial Metrics

Collaboration Revenue: Century generated $6.6 million in collaboration revenue from its partnership with Bristol-Myers Squibb, a notable increase from $2.2 million in 2023.

Research and Development Expenses: R&D expenses rose to $107.2 million, compared to $92.7 million in 2023, primarily driven by costs associated with the ELiPSE-1 trial and the CALiPSO-1 trial start-up.

General and Administrative Expenses: G&A expenses decreased to $33.2 million in 2024 from $34.7 million in the previous year due to a reduction in workforce.

Net Loss: The net loss for the year was $126.6 million, a slight improvement from the $136.7 million loss reported in 2023.

Implications of Financial Performance

Despite the operational challenges reflected in the financial results, Century Therapeutics remains committed to advancing its promising pipeline. The increase in collaboration revenue and strategic trial expansions indicate a focused approach to enhancing shareholder value and addressing unmet medical needs in the therapeutic landscape.

3. Looking Ahead

Century Therapeutics is set to host a live webcast on April 22, 2025, where the management will delve deeper into its prioritized programs, including the innovative Allo-Evasion™ 5.0 technology. The company aims to leverage this technology to develop allogeneic cell therapies that can be produced at scale and at a lower cost than traditional therapies.

Chad Cowan, Ph.D., Chief Scientific Officer, noted the company's ambition to "unlock an opportunity to replace current therapies and expand the application of cell therapy to areas with serious medical need."

As Century navigates through its strategic re-prioritization, stakeholders will be keenly observing its progress in the coming months, particularly as data from clinical trials begins to emerge in 2025.

Original press release